PX-3

PX-3
Legal status
Legal status	CA: Schedule II ; DE: NpSG (Industrial and scientific use only) ; UK: Under Psychoactive Substances Act ; Illegal in Sweden;
Identifiers
	IUPAC name N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide;
CAS Number	1185887-14-2;
PubChem CID	44206137;
ChemSpider	48063640;
UNII	3877T06H05;
Chemical and physical data
Formula	C24H28N4O2
Molar mass	404.5 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC(=O)[C@H](Cc1ccccc1)NC(=O)c2nn(CC3CCCCC3)c4ccccc24;
	InChI InChI=1S/C24H28N4O2/c25-23(29)20(15-17-9-3-1-4-10-17)26-24(30)22-19-13-7-8-14-21(19)28(27-22)16-18-11-5-2-6-12-18/h1,3-4,7-10,13-14,18,20H,2,5-6,11-12,15-16H2,(H2,25,29)(H,26,30)/t20-/m0/s1; Key:DMHWDSGURMXMGE-FQEVSTJZSA-N;

PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB₁ receptor with a binding affinity of K_i = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[1][2][3][4]

The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014.[5][6]

Legality

Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.[7]

References

"APP-CHMINACA". Cayman Chemical. Retrieved 24 June 2015.
"Patent WO/2009/106980 - Indazole derivatives". Cite journal requires |journal= (help)
"EWS Forum - In Belgien wurde die neue psychoaktive Substanz N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(cyclohexylmethyl)indazole-3-carboxamide (APP-CHMINACA) identifiziert". Retrieved 24 June 2015.
Presley, Brandon C.; Logan, Barry K.; Jansen-Varnum, Susan A. (October 2019). "In Vitro Metabolic Profile Elucidation of Synthetic Cannabinoid APP-CHMINACA (PX-3)". Journal of Analytical Toxicology. doi:10.1093/jat/bkz086. PMID 31665324.
"EWS Forum - In Schweden wurde die neue psychoaktive Substanz N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-APP-PICA) identifiziert". Retrieved 24 June 2015.
"EWS Forum - In Schweden wurden folgende drei neue psychoaktive Substanzen identifiziert". Retrieved 24 June 2015.
"23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 29 June 2015.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "APP-CHMINACA". Cayman Chemical. Retrieved 24 June 2015.

[2] "Patent WO/2009/106980 - Indazole derivatives". Cite journal requires |journal= (help)

[3] "EWS Forum - In Belgien wurde die neue psychoaktive Substanz N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(cyclohexylmethyl)indazole-3-carboxamide (APP-CHMINACA) identifiziert". Retrieved 24 June 2015.

[4] Presley, Brandon C.; Logan, Barry K.; Jansen-Varnum, Susan A. (October 2019). "In Vitro Metabolic Profile Elucidation of Synthetic Cannabinoid APP-CHMINACA (PX-3)". Journal of Analytical Toxicology. doi:10.1093/jat/bkz086. PMID 31665324.

[5] "EWS Forum - In Schweden wurde die neue psychoaktive Substanz N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-APP-PICA) identifiziert". Retrieved 24 June 2015.

[6] "EWS Forum - In Schweden wurden folgende drei neue psychoaktive Substanzen identifiziert". Retrieved 24 June 2015.

[7] "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 29 June 2015.

PX-3

Legality

See also

References